Search Results

You are looking at 1 - 10 of 92 items for :

Clear All
Full access

Matthew P. Banegas, Donna R. Rivera, Maureen C. O’Keeffe-Rosetti, Nikki M. Carroll, Pamala A. Pawloski, David C. Tabano, Mara M. Epstein, Kai Yeung, Mark C. Hornbrook, Christine Lu and Debra P. Ritzwoller

Background In 2018, approximately 8,430 patients were diagnosed with chronic myeloid leukemia (CML) and 1,090 patients died of the disease in the United States. 1 Treatment advances in CML using targeted oral therapies have led to dramatic

Full access

Susan O'Brien, Ellin Berman, Joseph O. Moore, Javier Pinilla-Ibarz, Jerald P. Radich, Paul J. Shami, B. Douglas Smith, David S. Snyder, Hema M. Sundar, Moshe Talpaz and Meir Wetzler

C hronic myelogenous leukemia (CML) is a stem cell malignancy that is characterized by a reciprocal translocation between chromosomes 9 and 22 [t(9;22)], resulting in the formation of the Philadelphia chromosome. This translocation results in the

Full access

Giuseppe Saglio and Carmen Fava

Chronic myelogenous leukemia (CML) is a clonal stem cell disease characterized by the presence of the BCR-ABL oncogene, whose endowed and constitutively activated tyrosine kinase activity leads to increased proliferation and genomic instability of

Full access

Paul J. Shami

, nilotinib, and dasatinib, based on a review Describe the case for the use of imatinib in first-line therapy of CML, based on a review Describe the case for the use of dasatinib or nilotinib in first-line therapy of CML, based on a review

Full access

Jorge Cortes, Clara Chen, Michael Mauro, Neela Kumar, Catherine Davis and Stuart L. Goldberg

Introduction: Dosing patterns of nilotinib (NIL) in chronic phase chronic myelogenous leukemia (CP-CML) patients (Pts) have not been well documented outside of clinical trials. SIMPLICITY (NCT01244750) is an ongoing observational study exploring

Full access

Stephen Harnicar

phase chronic myelogenous leukemia (CML). Current medications include: Levothyroxine, 50 mcg daily Metoprolol XL, 100 mg daily Lisinopril, 10 mg daily Warfarin, 5 mg daily Pantoprazole, 40 mg daily Multivitamin, 1

Full access

Jerald P. Radich, Michael Deininger, Camille N. Abboud, Jessica K. Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Peter Curtin, Daniel J. DeAngelo, Jason Gotlib, Gabriela Hobbs, Madan Jagasia, Hagop M. Kantarjian, Lori Maness, Leland Metheny, Joseph O. Moore, Arnel Pallera, Philip Pancari, Mrinal Patnaik, Enkhtsetseg Purev, Michal G. Rose, Neil P. Shah, B. Douglas Smith, David S. Snyder, Kendra L. Sweet, Moshe Talpaz, James Thompson, David T. Yang, Kristina M. Gregory and Hema Sundar

Chronic myeloid leukemia (CML) accounts for 15% of adult leukemias. The median age of disease onset is 67 years; however, CML occurs in all age groups (SEER statistics). In 2018, an estimated 8,430 people will be diagnosed with CML in the United States

Full access

Jorge Cortes, John M. Goldman and Timothy Hughes

The treatment landscape for chronic myelogenous leukemia (CML) dramatically changed after the FDA approved the tyrosine kinase inhibitor (TKI) imatinib mesylate (Gleevec, Novartis) in 2001. Imatinib targets BCR-ABL, a fusion protein expressed by

Full access

Michael W. Deininger, Neil P. Shah, Jessica K. Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Daniel J. DeAngelo, Jason Gotlib, Gabriela Hobbs, Lori Maness, Monica Mead, Leland Metheny, Sanjay Mohan, Joseph O. Moore, Kiran Naqvi, Vivian Oehler, Arnel M. Pallera, Mrinal Patnaik, Keith Pratz, Iskra Pusic, Michal G. Rose, B. Douglas Smith, David S. Snyder, Kendra L. Sweet, Moshe Talpaz, James Thompson, David T. Yang, Kristina M. Gregory and Hema Sundar

Overview Chronic myeloid leukemia (CML) accounts for 15% of adult leukemias. The median age of disease onset is 67 years; however, CML occurs in all age groups (SEER statistics). In 2020, an estimated 8,450 people will be diagnosed with CML in the

Full access

Jane Apperley

T he use of tyrosine kinase inhibitors (TKIs) in the management of chronic myelogenous leukemia (CML) has changed the natural course of the disease to such an extent that considerations regarding quality of life have become almost as important as